About Course #Y8012
Start Date: September 10, 2019
Expiration Date: September 10, 2022
Hypertension (HTN) is a common disease that affects millions of Americans without any warning. It is defined as a persistent elevated blood pressure and is a significant risk factor for cardiovascular disease, thus early detection is imperative. Increasing screening and diagnosis of HTN, and improving control of BP with appropriate treatment are important preventative measures to reduce CV morbidity and mortality. Therefore, a systematic understanding of the management of HTN is essential for pharmacists working in direct patient care to help further improve HTN control.
The purpose of this course is to increase the knowledge of pharmacists on the diagnosis, counseling, and management of HTN. Pharmacists will be able to select and implement appropriate first-line and add-on treatment for the management of HTN based on current evidence-based practice guidelines and identify appropriate therapeutic goals based on stages of HTN and comorbidities.
Universal Activity Number (UAN) - 0607-0000-19-014-H01-P
Type of Activity - Knowledge
Topic Designator - 01 - Disease State Management/Drug Therapy
- Define hypertension (HTN), the diagnostic criteria of HTN, and the overall purpose of treating HTN.
- Compare and contrast the differences between essential HTN and secondary causes of HTN.
- Describe the pathophysiology of HTN and the regulation of blood pressure (BP).
- Identify the cardiovascular (CV) complications that are associated with HTN and related target-organ damage.
- Interpret the key differences among various clinical treatment HTN guidelines.
- Recognize appropriate ambulatory and home BP monitoring and measurement.
- Describe important elements of patient counseling regarding HTN, lifestyle modification, and drug therapy.
- List clinical considerations of antihypertensive agents.
- Outline evidenced-based pharmacotherapy options used to treat patients with HTN with or without compelling indications, and describe supporting evidence for these recommendations.
- Choose appropriate drug therapy and monitoring plans for patients with HTN.
About the Author(s)
Thom Kim Nguyen, PharmD, BCPS, CTTS, is a clinical assistant professor of pharmacy practice at the Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey in Piscataway, New Jersey. Dr. Nguyen received her doctor of pharmacy (PharmD) degree from the Ernest Mario School of Pharmacy. She completed 2 years of postgraduate residency training in pharmacy practice and in pharmacotherapy with a focus on ambulatory care. She also obtained board certification in pharmacotherapy in 2013 and tobacco treatment and medication therapy management in 2014. Dr. Nguyen is a member of several national and state pharmacy organizations, including the American Society of Health-System Pharmacists (ASHP), the American College of Clinical Pharmacy (ACCP), and the New Jersey Society of Health-System Pharmacists (NJSHP).
- Courses must be completed on or before the expiration date noted in the course description above.
- You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
- Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools' policy not to accept commercial support.
- All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.